Fund moves

Boston Scientific (BSX): E Fund Management Co., Ltd. reduced its stake -65K shares

E Fund Management Co., Ltd. reduced its stake in Boston Scientific, per its Q2 2025 13F.

6,442
Shares reported · -65K vs prior quarter
0.03%
Disclosed portfolio weight
$692K
Reported value
Holdings as of
Jun 30, 2025
Filed
Aug 15, 2025

What stands out in this filing

  • 71,560 shares in Q1 2025, 6,442 now (−91.0% in share count).
  • Reported at $692K, 0.03% of the portfolio value in this 13F filing.
  • 74 other tracked managers reported the same kind of change for Q2 2025.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 29, 2024CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  2. Dec 11, 2024CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  3. May 12, 2025CongressDisclosed sale of BSX — reported range $15,001 - $50,000
  4. Jun 11, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  5. Jun 26, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  6. Jul 1, 2025InsiderOfficer sold ~$5.35M of BSX shares in the open market
  7. Jul 25, 2025InsiderDirector sold ~$424K of BSX shares in the open market
  8. Jul 29, 2025InsiderDirector sold ~$310K of BSX shares in the open market
  9. Jul 31, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  10. Aug 1, 2025Insider · 2 peopleInsiders: 2 sales (~$7.0M)
  11. Aug 4, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000

What came next

  1. Sep 2, 2025Insider · 1 personInsiders: 2 sales (~$5.3M)
  2. Sep 11, 2025FDARecall: TENACIO Pump without InhibiZone; UPN: 72404420;
  3. Sep 11, 2025FDARecall: TENACIO Pump with InhibiZone; UPN: 72404429;
  4. Sep 11, 2025FDARecall: LGX Preconnect with TENACIO Pump without InhibiZone; UPNs: (1) 72404405 (12CM IP), (2) 72404407 (18CM IP);
  5. Sep 11, 2025FDARecall: CXR Preconnect with TENACIO Pump with InhibiZone; UPNs: (1) UPN: 72404461 (12CM PS IZ), (2) 72404462 (14CM PS IZ), (3) 72404463 (16CM PS IZ), (4) 72404464 (18C…
  6. Sep 11, 2025FDARecall: CX Preconnect with TENACIO Pump without InhibiZone; UPNs: (1) 72404486 (15CM IP), (2) 72404488 (21CM IP);
  7. Sep 11, 2025FDARecall: LGX Preconnect with TENACIO Pump with InhibiZone; UPNs: (1) UPN: 72404450 (12CM PS IZ), (2) 72404451 (15CM PS IZ), (3) 72404452 (18CM PS IZ), (4) 72404453 (21C…
  8. Sep 11, 2025FDARecall: CX Preconnect with TENACIO Pump with InhibiZone; UPNs: (1) UPN: 72404430 (12CM PS IZ), (2) 72404431 (15CM PS IZ), (3) 72404432 (18CM PS IZ), (4) 72404433 (21CM…
  9. Sep 12, 2025FDAFDA device clearance: LUX-Dx II Insertable Cardiac Monitor (M302); LUX-Dx II+ Insertable Cardiac Monitor (M312)
  10. Sep 23, 2025CongressDisclosed sale of BSX — reported range $1,001 - $15,000
  11. Sep 24, 2025FDAFDA device clearance: LithoVue Elite Single-Use Digital Flexible Ureteroscope - Standard with pressure monitoring (M0067940000); LithoVue Elite Single-Use Digital Flexible Ureterosc…
  12. Sep 26, 2025FDAFDA device clearance: Radial Jaw 4 Pulmonary Biopsy Forceps
  13. Oct 9, 2025FDAFDA device clearance: Orca Air/Water and Suction Valves
  14. Oct 17, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  15. Oct 22, 2025Company filing · Form 8-K · ResultsReported its results
  16. Oct 22, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 22, 2025, John E. Sununu informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
  17. Oct 27, 2025InsiderDirector sold ~$1.01M of BSX shares in the open market
  18. Oct 28, 2025FDAFDA device clearance: TheraSphere 360™ Y-90 Management Platform
  19. Oct 28, 2025InsiderDirector sold ~$297K of BSX shares in the open market
  20. Oct 28, 2025CongressDisclosed partial sale of BSX — reported range $15,001 - $50,000
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Boston Scientific

For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.

How this filing works

Explore the data

Common questions

What does this filing report about Boston Scientific (BSX) stock?

E Fund Management Co., Ltd. reduced its stake in Boston Scientific, per its Q2 2025 13F. Now 6,442 shares, $692K reported value, 0.03% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Jun 30, 2025. Filed: Aug 15, 2025.

What stands out in this filing?

71,560 shares in Q1 2025, 6,442 now (−91.0% in share count). Reported at $692K, 0.03% of the portfolio value in this 13F filing. 74 other tracked managers reported the same kind of change for Q2 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Boston Scientific recently?

For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days. They are listed on the BSX page.

Does this mean BSX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Boston Scientific

Everything OQRO holds on this company is on its BSX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data